HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1-bromoacetyl-3,3-dinitroazetidine

has antineoplastic activity; structure in first source

Also Known As:

ABDNAZ

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azetines
    - Azetidines: 6
      - 1-bromoacetyl-3,3-dinitroazetidine: 1
Organic Chemicals: 133
- Nitro Compounds: 66
  - 1-bromoacetyl-3,3-dinitroazetidine: 1

Experts

1.	Bednarski, Mark: 1 article (05/2012)
2.	Knox, Susan J: 1 article (05/2012)
3.	Ning, Shoucheng: 1 article (05/2012)
4.	Oronsky, Bryan: 1 article (05/2012)
5.	Saul, Gordon: 1 article (05/2012)
6.	Scicinski, Jan: 1 article (05/2012)

Related Diseases

1.

Neoplasms (Cancer)

05/15/2012 - "However, compared with cisplatin, ABDNAZ was better tolerated at submaximal doses, yielding significant tumor growth inhibition in the absence of systemic toxicity. "
05/15/2012 - "In tumor cell culture, ABDNAZ generated reactive free radicals in a concentration- and time-dependent manner, modulating intracellular redox status and triggering apoptosis. "
05/15/2012 - "In this study, we report the preclinical validation of 1-bromoacetyl-3,3-dinitroazetidine (ABDNAZ), a representative lead compound currently in a phase I clinical trial in patients with cancer. "

Related Drugs and Biologics

1.	1-bromoacetyl-3,3-dinitroazetidine
2.	Free Radicals
3.	Cisplatin (Platino)